Capricor Therapeutics is developing therapeutics for Duchenne muscular dystrophy and had a Type A meeting scheduled with the FDA.
3 reports, 1 independent
Updated Aug 10
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Capricor Therapeutics is developing therapeutics for Duchenne muscular dystrophy and had a Type A meeting scheduled with the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Capricor scheduled a Type A meeting with the FDA regarding its DMD therapeutics.1 source
The company is also using social media (Twitter/Instagram) for company communication.1 source
Keep exploring
Part of
Capricor Therapeutics is seeking regulatory approval from the FDA for therapeutics targeting Duchenne Muscular Dystrophy.Also in this story
- The FDA is reviewing the Biologics License Application (BLA) submission from Capricor Therapeutics regarding its therapeutics for Duchenne Muscular Dystrophy (DMD).
- The FDA informed Capricor Therapeutics that regulatory review is not required for its drug.
The entities involved
- FDA
-
Capricor Therapeutics (United States)
company in Beverly Hills, United States
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireCapricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA – Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET – SAN DIEGO
- GlobeNewswireCapricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13 – Company to Host Conference Call on August 13, 2025, at 4:30 p.m. ET – SAN DIEGO, Aug.